Recombinant Human VEGF 165 Protein, CF 293-VE-010/CF from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human VEGF 165 Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $404.00Supplier Page View Company Product Page
Catalog Number293-VE-010/CF
SpeciesHuman
FormatLyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA with trehalose
Molecule NameVEGF
Size10 ug (also 50 ug, 500 ug, 1 mg)
Source/Expression SystemSf 21 (baculovirus)-derived Recombinant Human VEGF 165 Protein, CF
NCBI Full Gene Namevascular endothelial growth factor A
NCBI Gene AliasesMVCD1, VPF, VEGF
Molecular WeightObserved: 20-22 kDa, under reducing conditions. 39-42 kDa, under non-reducing conditions.
Theoretical: 19.2 kDa (monomer)
ApplicationsBioactivity
Conjugate/TagUnconjugated
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution
Purity>97%, by SDS-PAGE under reducing conditions and visualized by silver stain

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Revisiting the F3 Peptide: In Vitro Investigations of C- and N-Terminally Modified Peptide Conjugates for Radiotracer DevelopmentPharmaceuticals (Basel)March 31, 2026Maximilian Anderla, Marlene Grillmayr, Katharina Huemer, Thomas L. MindtGermany) (cat. no. SCME002). Recombinant human VEGF was from R&D Systems (Minneapolis, MN, USA) (cat. no. 293-VE-010/CF). Pooled human serum (“off the clot”) was purchased from Innovative Research (Novi, MI, USA). Radiolabeling

(2) An elastin-like polymer targeting vascular endothelial growth factor receptor-1 reduces survival in serum-starved endothelial cellsBiochemical Engineering JournalJanuary 1, 2026M. Lisa Phipps, Antonietta M. Lillo, Demosthenes P. Morales, Miriam Hernandez-Romero, Leyma P. De Haro, Devin Close, Wynter A. Paiva, Emily K. Funsten, Andrew R. M. Bradbury, Jennifer S. Martinez, et al.(#CC-5036), and media supplements (#CC-4542) were purchased from Lonza. Recombinant human VEGF165 (#293-VE-010/CF) was from R&D Systems. R1B peptide (CPQPRPLC) (purity >98%) was from Genscript. Recombinant human vitronectin

(3) A Complementarity‐Based Approach to De Novo Binder DesignAdvanced ScienceSeptember 1, 2025Kateryna Maksymenko, Valeriia Hatskovska, Murray Coles, Narges Aghaallaei, Natalia Pashkovskaia, Natalia Borbarán‐Bravo, Matteo Pilz, Philip Bucher, Mareike Volz, Joana Pereira, et al.Biacore X100 system (GE Healthcare Life Sciences). Recombinant Human VEGF165 (rhVEGF) (R&D Systems, 293‐VE‐010/CF) was diluted to 50 µg mL−1 in 10 mm acetate buffer pH 5.0 and immobilized on the surface of a CM5 sensor

(4) VEGF in Tears as a Biomarker for Exudative Age-Related Macular Degeneration: Molecular Dynamics in a Mouse Model and Human SamplesInt J Mol SciApril 18, 2025Seyed Mohamad Mehdi Moshtaghion, Filippo Locri, Alvaro Plaza Reyes, Flavia Plastino, Anders Kvanta, Maria Jose Morillo-Sanchez, Enrique Rodríguez-de-la-Rúa, Estanislao Gutierrez-Sanchez, Adoración Montero-Sánchez, Helena Lucena-Padros, et al.supplements, along with 0, 50, 100, or 200 ng/mL of recombinant human VEGF 165 protein (R&D Systems; cat no 293-VE-010/CF) for 48 h. The LGs were maintained in a standard cell culture incubator (20% oxygen, 5% carbon dioxide

(5) Mitochondrial fusion and cristae reorganization facilitate acquisition of cardiomyocyte identity during reprogramming of murine fibroblastsCell ReportsMarch 25, 2025Brian M. Spurlock, Yifang Xie, Yiran Song, Shea N. Ricketts, James Rock Hua, Haley R. Chi, Meenakshi Nishtala, Rustem Salmenov, Jiandong Liu, Li QianRecombinant Human FGF-10 Protein,R&D Systems,Cat# 345-FG-025/CF Recombinant Human VEGF 165 Protein R&D Systems 293-VE-010/CF,R&D Systems,Cat# 293-VE-010/CF Reynold’s lead citrate,Reynold’s,Cat# 1963 Rotenone,Sigma,Cat# R8875 Sodium

(6) ETV2/ER71 regulates hematovascular lineage generation and vascularization through an H3K9 demethylase, KDM4AiScienceJanuary 17, 2025Min Seong Kim, Raham Lee, Dong Hun Lee, Heesang Song, Taekyung Ha, Joo Kyung Kim, Bum-Yong Kang, Karl Agger, Kristian Helin, Donghyun Shin, et al.,Sigma Aldrich,Cat# 16-662 Random primers,Promega,Cat# C1181 Recombinant human VEGF 165 protein,Bio Techne,Cat# 293-VE-010/CF Recombinant mouse LIF protein,Sigma Aldrich,Cat# ESG1106 RNaseOUT,Thermofisher Scientific,Cat# 10777019 SuperScript IV Reverse Transcriptase

(7) Modeling early pathophysiological phenotypes of diabetic retinopathy in a human inner blood-retinal barrier-on-a-chipNature communicationsFebruary 14, 2024Maurissen TL, Spielmann AJ, Schellenberg G, Bickle M, Vieira JR, Lai SY, Pavlou G, Fauser S, Westenskow PD, Kamm RD, et al.

(8) Requirement of Site-Specific Tyrosine Phosphorylation of Cortactin in Retinal Neovascularization and Vascular LeakageArteriosclerosis, Thrombosis, and Vascular BiologyFebruary 1, 2024Raj Kumar, Klemens Rottner, Gadiparthi N. Raofrom the corresponding author upon reasonable request. Reagents Recombinant human VEGF165a (Cat No. 293-VE-010/CF) and Mouse VEGFA 164a (Cat No. 493-MV-025/CF) were bought from R&D Systems (Minneapolis, MN). Growth

(9) Acrizanib as a Novel Therapeutic Agent for Fundus Neovascularization via Inhibitory Phosphorylation of VEGFR2Translational Vision Science & TechnologyJanuary 2, 2024Xiaoyu Tang, Kaixuan Cui, Peiqi Wu, Andina Hu, Matthew Fan, Xi Lu, Fengmei Yang, Jicheng Lin, Shanshan Yu, Yue Xu, et al.In VEGF-treated experiments, HUVECs were treated with complete medium containing 10 ng/mL VEGF (no. 293-VE-010/CF; R&D Systems, Minneapolis, MN, USA) referring to the previous study.25 The methodological details of

(10) Alternative method to visualize receptor dynamics in cell membranesPloS oneJanuary 1, 2024Cosetta R, Michela C, Anna V, Mattia D, Elisabetta G, Stefania M.#10010023).Bovine Serum Albumin (BSA) (Thermofisher #15561020).Recombinant VEGF-A165 (R&D system, #293-VE-010/CF). Equipment ● Cell culture incubator. Epifluorescence microscope equipped with structured illumination

(11) Peptide Nanofiber System for Sustained Delivery of Anti-VEGF Proteins to the Eye VitreousPharmaceuticsApril 18, 2023Yaylaci S, Dinç E, Aydın B, Tekinay AB, Guler MO.immunoassay, all samples were diluted. The 165-amino acid variant of human recombinant VEGF (R&D Systems, 293-VE-010/CF) was immobilized on high-binding plates suitable for luminescent detection. The VEGF was put onto each

(12) An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zoneExperimental & molecular medicineFebruary 1, 2023Lee E, Lee EA, Kong E, Chon H, Llaiqui-Condori M, Park CH, Park BY, Kang NR, Yoo JS, Lee HS, et al.

(13) Sesamin Attenuates VEGFA-Induced Angiogenesis via Inhibition of Src and FAK Signaling in Chick Chorioallantoic Membrane Model and Human Endothelial EA.hy926 CellsBiomedicinesJanuary 11, 2023Keratibumrungpong T, Srisuthtayanont W, Wanachewin O, Klangjorhor J, Phitak T, Pothacharoen P, Shwe TH, Kongtawelert P.

(14) Effect of triamcinolone acetonide on retinal inflammation and angiogenesis induced by pericyte depletion in mouseJournal of pharmacological sciencesJanuary 1, 2023Otsuka T, Masuda T, Takahashi Y, Suzuki A, Uemura A, Arakawa R, Okabe T, Naito A.

(15) Susceptibilities of CNS Cells towards Rabies Virus Infection Is Linked to Cellular Innate Immune ResponsesVirusesDecember 29, 2022Feige L, Kozaki T, Dias de Melo G, Guillemot V, Larrous F, Ginhoux F, Bourhy H.

(16) DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularizationScientific reportsDecember 13, 2022Zhang H, Li B, Ding J, Ye R, Xu Z, Zhang Q, Feng S, Jiang Q, Zhu W, Yan B.

(17) Human iPSC-hepatocyte modeling of alpha-1 antitrypsin heterozygosity reveals metabolic dysregulation and cellular heterogeneityCell reportsDecember 6, 2022Kaserman JE, Werder RB, Wang F, Matte T, Higgins MI, Dodge M, Lindstrom-Vautrin J, Bawa P, Hinds A, Bullitt E, et al.

(18) Glycine inhibits NINJ1 membrane clustering to suppress plasma membrane rupture in cell deatheLifeDecember 5, 2022Borges JP, Sætra RSR, Volchuk A, Bugge M, Devant P, Sporsheim B, Kilburn BR, Evavold CL, Kagan JC, Goldenberg NM, et al.

(19) Angiogenic adipokine C1q-TNF-related protein 9 ameliorates myocardial infarction via histone deacetylase 7-mediated MEF2 activationScience advancesDecember 2, 2022Lee SM, Lee JW, Kim I, Woo DC, Pack CG, Sung YH, Baek IJ, Jung CH, Kim YH, Ha CH.

(20) Long non-coding RNA PCAT19 safeguards DNA in quiescent endothelial cells by preventing uncontrolled phosphorylation of RPA2Cell reportsNovember 15, 2022Oo JA, Pálfi K, Warwick T, Wittig I, Prieto-Garcia C, Matkovic V, Tomašković I, Boos F, Izquierdo Ponce J, Teichmann T, et al.

Write a Review

(1)

7/21/2017Effect Of VEGFA On Retinal Endothelial Cell Migration Anonymous ReviewerVEGFA induces human retinal endothelial cell migration. VEGFA was used at a concentration of 40 ng/ml and the migration of human retinal endothelial cells was measured by wound healing assay.

Recombinant Human VEGF 165 Protein, CF

VEGF 165 Protein

VEGF 165 Protein

VEGF 165 Protein

Recombinant Human VEGF 165 Protein, CF from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (449)

Reviews

Recombinant Human VEGF 165 Protein, CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map